Last reviewed 2026-04-23 · How we verify

AZD8871

AZD8871 is a small molecule that targets the PI3K delta inhibitor.

AZD8871 is a small molecule that targets the PI3K delta inhibitor. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).

At a glance

Mechanism of action

AZD8871 works by selectively inhibiting the PI3K delta enzyme, which plays a key role in the activation of immune cells. This inhibition can help to reduce inflammation and modulate the immune response. By targeting PI3K delta, AZD8871 aims to provide a therapeutic benefit in various diseases.

Approved indications

• Relapsed or refractory chronic lymphocytic leukemia (CLL)

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia

Key clinical trials

• A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. (PHASE2)
• Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871 (PHASE2)
• Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects (PHASE1)
• Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects (PHASE1)
• Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AZD8871 CI brief — competitive landscape report
• AZD8871 updates RSS · CI watch RSS
• AstraZeneca portfolio CI